Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

Share Price is delayed by 15 minutes
Get Live Data
112.15    0.45 (0.40%)
Bid:
112.15
Ask:
112.20
Spread: 0.05 (0.045%)
Market Cap: £65.20b
LLOY Live PriceLast checked at - London Stock Exchange

Intraday Lloyds Share Chart

Publication of Final Terms

18 Mar 2026 17:06

RNS Number : 2048X
Lloyds Bank PLC
18 March 2026
 

18 March 2026

 

Lloyds Bank plc

LEI: H7FNTJ4851HG0EXQ1Z70

Publication of Final Terms

The following Final Terms under the €60 billion Global Covered Bond Programme of Lloyds Bank plc are available for viewing:

£1,500,000,000 Series 2026-1 Floating Rate Covered Bonds due March 2029

To view the Final Terms, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/2048X_1-2026-3-18.pdf

The Final Terms has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

 

Investor Relations

Douglas Radcliffe

Group Investor Relations Director

Email: douglas.radcliffe@lloydsbanking.com

 

 

+44 (0) 20 7356 1571

 

Group Corporate Affairs

Matt Smith

Head of Media Relations

Email: matt.smith@lloydsbanking.com

 

 

+44 (0) 7788 352 487

Group Corporate Treasury

Kristofer Middleton

Head of Term Issuance and Capital Structuring

Email: Kristofer.Middleton@lloydsbanking.com

 

+44 (0) 20 7356 1122

 

Head of Debt Investor Relations

 

Niamh O'Connor

Head of Debt Investor Relations

Email: Niamh.O'Connor@lloydsbanking.com

+44 (0) 7350 418011

 

Lloyds Bank plc

Registered Office

25 Gresham Street

London EC2V 7HN

 

Disclaimer - Intended Addressees

Please note that the information contained in this announcement and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and Final Terms are not addressed. Prior to relying on the information contained in this announcement and the Final Terms, you must ascertain from the Base Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Final Terms.

In particular, this announcement and the Final Terms do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Final Terms are not for distribution in the United States or to U.S. persons (as defined below). The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the Securities Act) or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. The securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the Securities Act) except pursuant to registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. For a description of the restrictions on offers and sales of the securities described herein, please refer to the Supplementary Prospectus and Base Prospectus.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTUWRBRNOUOAAR
Date   Source Headline
22nd Feb 20244:13 pmRNS2023 Form 20F Filed
22nd Feb 20247:00 amRNSBoard Changes
22nd Feb 20247:00 amRNS2023 Full Year Results
22nd Feb 20247:00 amRNS2023 Annual Report and Accounts
20th Feb 20242:05 pmRNSReplacement Block listing Interim Review
20th Feb 20242:00 pmRNSReplacement Block listing Interim Review
15th Feb 20247:00 amRNSBoard Change
31st Jan 20243:56 pmRNSTotal Voting Rights
25th Jan 20245:07 pmRNSBoard Committee Change
11th Jan 20242:00 pmRNSDirector/PDMR Shareholding
5th Jan 20241:50 pmRNSPublication of Final Terms
2nd Jan 202412:00 pmRNSBlock listing Interim Review
29th Dec 202310:30 amRNSTotal Voting Rights
18th Dec 20232:30 pmRNSBoard Committee Change
18th Dec 20232:00 pmRNSDirector/PDMR Shareholding
12th Dec 20234:00 pmRNSDirector/PDMR Shareholding
30th Nov 20232:00 pmRNSTotal Voting Rights
20th Nov 20232:00 pmRNSBlock Listing of Shares
10th Nov 20234:00 pmRNSDirector/PDMR Shareholding
6th Nov 20233:57 pmRNSPublication of Final Terms
31st Oct 202311:20 amRNSTotal Voting Rights
26th Oct 20233:47 pmRNSPublication of Suppl.Prospcts
26th Oct 20231:02 pmRNSPublication of Suppl.Prospcts
26th Oct 202312:59 pmRNSPublication of Suppl.Prospcts - Correction
25th Oct 202312:09 pmRNSPublication of Suppl.Prospcts
25th Oct 202311:57 amRNS2023 Q3 Interim Management Statement
25th Oct 20237:00 amRNS2023 Q3 Interim Management Statement
11th Oct 20232:00 pmRNSDirector/PDMR Shareholding
22nd Sep 20232:00 pmRNSDirector/PDMR Shareholding
21st Sep 20231:28 pmRNSPublication of Final Terms
20th Sep 20232:00 pmRNSDirector/PDMR Shareholding
15th Sep 20232:00 pmRNSDirector/PDMR Shareholding
13th Sep 20232:00 pmRNSBoard and Committee changes
13th Sep 20231:45 pmRNSDirector/PDMR Shareholding
13th Sep 20239:20 amRNS2023 Half-Year Results
31st Aug 202312:00 pmRNSTotal Voting Rights
29th Aug 20237:21 amRNSCompletion of £2 billion Share Buyback Programme
25th Aug 20235:51 pmRNSTransaction in Own Shares
24th Aug 20235:38 pmRNSTransaction in Own Shares
24th Aug 20235:30 pmRNSTotal Voting Rights
23rd Aug 20235:21 pmRNSTransaction in Own Shares
22nd Aug 20235:18 pmRNSTransaction in Own Shares
22nd Aug 202311:44 amRNSPublication of Pricing Supplement
22nd Aug 20239:39 amRNSStabilisation Notice
21st Aug 20235:14 pmRNSTransaction in Own Shares
18th Aug 20235:37 pmRNSTransaction in Own Shares
17th Aug 20235:39 pmRNSTransaction in Own Shares
16th Aug 20235:29 pmRNSTransaction in Own Shares
15th Aug 20235:28 pmRNSTransaction in Own Shares
14th Aug 20235:36 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.